Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

510
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
510
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
Neural Regulation01:37

Neural Regulation

39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Noradrenergic Brain in Parkinson's Disease.

Current neurology and neuroscience reports·2026
Same author

Essential Tremor and Digital Biomarkers: A Scoping Review Using the TRACE Framework to Map Readiness for Clinical Trials and Routine Practice.

Tremor and other hyperkinetic movements (New York, N.Y.)·2026
Same author

Timing of device-aided therapy initiation in Parkinson's disease: reference estimates for healthcare planning and biological heterogeneity.

Clinical parkinsonism & related disorders·2026
Same author

Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.

Lancet (London, England)·2026
Same author

Expanding PPMI through Remote Data Acquisition and Analysis: Early Success and Future Growth with myPPMI.

Annals of neurology·2026
Same author

Recruitment Strategies across the Spectrum of Neuronal Synuclein Disease.

Annals of neurology·2026
Same journal

Beyond the High: A Narrative Review of the Chronic Complications of Recreational Ketamine Use.

British journal of hospital medicine (London, England : 2005)·2026
Same journal

Prolonged Undiagnosed Prodromal Symptoms.

British journal of hospital medicine (London, England : 2005)·2026
Same journal

Human Factors and Deterioration: What Success Factors Facilitate Escalation of Care and How Can These Be Applied More Reliably?

British journal of hospital medicine (London, England : 2005)·2026
Same journal

Comparative Evaluation of Functional Outcomes and Postoperative Complications After Minimally Invasive Fixation for Acromioclavicular Joint Injuries.

British journal of hospital medicine (London, England : 2005)·2026
Same journal

A Systematic Review of Functional MRI Studies on Seasonal Modulation of Brain Functional Connectivity.

British journal of hospital medicine (London, England : 2005)·2026
Same journal

More Than Myocarditis? Cardiac Involvement in Phaeochromocytoma-A Case Report.

British journal of hospital medicine (London, England : 2005)·2026
See all related articles

Related Experiment Video

Updated: Jun 18, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.0K

Parkinson's, where are we heading?

Nicola Pavese1, David Ledingham1

  • 1Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, UK.

British Journal of Hospital Medicine (London, England : 2005)
|July 30, 2024
PubMed
Summary
This summary is machine-generated.

Parkinson's disease research is advancing, focusing on alpha-synuclein's role. New diagnostic tests, staging systems, and therapies targeting alpha-synuclein show promise for Parkinson's disease management.

Keywords:
Neuronal α-synuclein diseaseParkinson’sα-synuclein seeding amplification assay

More Related Videos

Locomotor Assessment of 6-Hydroxydopamine-induced Adult Zebrafish-based Parkinson's Disease Model
07:32

Locomotor Assessment of 6-Hydroxydopamine-induced Adult Zebrafish-based Parkinson's Disease Model

Published on: December 28, 2021

3.9K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.2K

Related Experiment Videos

Last Updated: Jun 18, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.0K
Locomotor Assessment of 6-Hydroxydopamine-induced Adult Zebrafish-based Parkinson's Disease Model
07:32

Locomotor Assessment of 6-Hydroxydopamine-induced Adult Zebrafish-based Parkinson's Disease Model

Published on: December 28, 2021

3.9K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.2K

Area of Science:

  • Neurology
  • Neuroscience
  • Biochemistry

Background:

  • Parkinson's disease prevalence is rising globally.
  • Alpha-synuclein aggregation is a key pathological hallmark.
  • Understanding alpha-synuclein is crucial for therapeutic development.

Discussion:

  • A novel cerebrospinal fluid alpha-synuclein diagnostic test is under development.
  • A new Parkinson's disease staging system incorporates alpha-synuclein, genetic, and neuro-imaging data.
  • Clinical trials utilizing monoclonal antibodies targeting alpha-synuclein have been completed.

Key Insights:

  • Alpha-synuclein is a central target for new Parkinson's disease investigations and therapies.
  • Integrating multi-modal data (alpha-synuclein, genetics, neuro-imaging) enhances disease staging.
  • Non-motor symptoms like hyposmia and cognitive decline are increasingly recognized.

Outlook:

  • Further research into alpha-synuclein pathways may yield disease-modifying treatments.
  • Personalized medicine approaches will likely integrate biomarker and genetic information.
  • Comprehensive management strategies must address both motor and non-motor symptoms.